Download our whitepaper,

"Navigating Neuropathic Pain: Bridging the Past and Future of Treatment Strategies"

Neuropathic Pain - iNGENū CRO

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for Neuropathic Pain Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for Neuropathic Pain.
  • Comprehensive Analysis of FDA-Approved Neuropathic Pain Drugs.
  • How Diagnostic Criteria for Neuropathic Pain Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in Neuropathic Pain Clinical Trials.
  • And additional insights to drive your trial's success.

Access your complimentary whitepaper today:

Neuropathic Pain

Neuropathic pain, a condition characterized by pain arising as a direct consequence of a lesion or disease affecting the somatosensory system, represents a significant clinical challenge and area of ongoing research.

Historically, neuropathic pain was poorly understood, with treatments focusing on symptom management without addressing underlying causes. Over time, advances in neuroscience have illuminated the complex mechanisms behind neuropathic pain, including the roles of the peripheral and central nervous systems, leading to more targeted and effective treatments. 

iNGENū’s team of researchers and clinicians is dedicated to advancing neuropathic pain research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by neuropathic pain.


Neuropathic pain affects approx.

7-10%

of the general population worldwide



 

About 60-70% of patients experience symptoms for more than

5 years

 



Neuropathic pain significantly impairs quality of life, affecting physical, emotional, and social well-being





Our clinical team has over

120

years of combined clinical trial experience